Geron (NASDAQ: GERN) grants EVP 2.22M stock options vesting monthly

Rhea-AI Filing Summary

Eid Joseph reported acquisition or exercise transactions in this Form 4 filing.

Geron Corporation reported that EVP, R&D and Chief Medical Officer Joseph Eid received a grant of stock options covering 2,220,000 shares. The options were awarded at a reported price of $0.00 per share and are held directly. The grant vests in 48 equal monthly installments starting on March 17, 2026, as long as he continues to provide service on each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eid Joseph

(Last) (First) (Middle)

C/O GERON CORPORATION

919 EAST HILLSDALE BOULEVARD, SUITE 250

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GERON CORP [ GERN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, R&D; Chief Medical Office

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.8	02/17/2026		A		2,220,000		(1)	02/16/2036	Common Stock	2,220,000	$0	2,220,000	D

Explanation of Responses:

1. The option vests in 48 equal monthly installments commencing on March 17, 2026, provided that the Reporting Person provides continuous service to the Issuer on each such vesting date.

	/s/ Michelle Robertson, attorney-in-fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Geron (GERN) report for Joseph Eid?

Geron reported that Joseph Eid received a grant of stock options for 2,220,000 shares. These derivative securities were awarded with a reported price of $0.00 per share and are held directly in his name.

How many Geron (GERN) stock options were granted to Joseph Eid?

Joseph Eid was granted stock options covering 2,220,000 shares of Geron common stock. This entire amount was acquired in a single award and represents derivative securities rather than currently outstanding common shares.

When do Joseph Eid’s Geron (GERN) stock options start vesting?

The stock options granted to Joseph Eid begin vesting on March 17, 2026. Vesting occurs in 48 equal monthly installments, contingent on his continued service with Geron on each monthly vesting date.

What is the vesting schedule for Joseph Eid’s Geron (GERN) option grant?

The option grant to Joseph Eid vests in 48 equal monthly installments. Vesting starts on March 17, 2026, and continues each month, provided he maintains continuous service to Geron on every scheduled vesting date.

Is Joseph Eid’s Geron (GERN) option grant a direct or indirect holding?

The Form 4 indicates that Joseph Eid’s stock option grant is a direct holding. The ownership code is reported as “D,” and no separate entity or indirect ownership structure is referenced in the filing or its footnotes.

What role does Joseph Eid hold at Geron (GERN) related to this Form 4?

In this Form 4, Joseph Eid is identified as an officer of Geron, serving as EVP, R&D and Chief Medical Office. The stock option grant relates to his position and ongoing service with the company.